San Diego, CA, United States of America

Charles Maxwell Lawrence


Average Co-Inventor Count = 7.0

ph-index = 2

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 2008

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Charles Maxwell Lawrence

Introduction

Charles Maxwell Lawrence is a notable inventor based in San Diego, CA. He has made significant contributions to the field of medicine through his innovative patents. With a total of 2 patents, Lawrence's work focuses on developing compounds that can treat various diseases.

Latest Patents

Lawrence's latest patents include "Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease." This patent discloses carbonyl compounds of Formula I, which are designed to treat a range of disease states, including cancers, autoimmune diseases, and neurodegenerative disorders. Additionally, it outlines methods for modulating the activity of histone deacetylase (HDAC). Another significant patent is "Sulfonamides as inhibitors of histone deacetylase for the treatment of disease," which also focuses on carbonyl compounds and their applications in treating similar disease states.

Career Highlights

Lawrence is currently associated with Kalypsys, Inc., where he continues to innovate and develop new therapeutic solutions. His work has the potential to impact numerous medical conditions, making him a valuable asset in the field of pharmaceutical research.

Collaborations

Some of his notable coworkers include James W Malecha and Stewart Alwyn Noble, who contribute to the collaborative efforts in research and development at Kalypsys, Inc.

Conclusion

Charles Maxwell Lawrence's contributions to the field of medicine through his patents demonstrate his commitment to innovation and improving health outcomes. His work continues to pave the way for advancements in the treatment of various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…